Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products

Do Yeon Kim; So Yeon Lee; Jae Yun Lee; Tae Woong Whon; June Young Lee; Che Ok Jeon; Jin Woo Bae

doi:10.1080/19490976.2024.2412376

Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products

Do Yeon Kim, So Yeon Lee, Jae Yun Lee, Tae Woong Whon, June Young Lee, Che Ok Jeon, Jin Woo Bae

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

The human intestine hosts a complex ecosystem of various microorganisms, collectively known as the gut microbiome, which significantly impacts human health. Disruptions in the gut microbiome are linked to various disorders, including gastrointestinal diseases, such as Clostridioides difficile infection and inflammatory bowel disease, as well as metabolic, neurological, oncologic conditions. Fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) have emerged as prospective therapeutic procedures to restore microbial and metabolic balance in the gut. This review assesses the latest advancements, challenges, and therapeutic efficacy of FMT and LBPs, highlighting the need for standardization, safety, and long-term evaluation to optimize their clinical application.

Original language	English
Article number	2412376
Journal	Gut Microbes
Volume	16
Issue number	1
DOIs	https://doi.org/10.1080/19490976.2024.2412376
Publication status	Published - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.

Keywords

CDI
FMT
Gut microbiome
IBD
LBP
cancer
dysbiosis
metabolic disorders
neurological disorders

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/19490976.2024.2412376

Cite this

@article{fd7f4ed5eaba48d3bbbbfed5f39b97da,

title = "Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products",

abstract = "The human intestine hosts a complex ecosystem of various microorganisms, collectively known as the gut microbiome, which significantly impacts human health. Disruptions in the gut microbiome are linked to various disorders, including gastrointestinal diseases, such as Clostridioides difficile infection and inflammatory bowel disease, as well as metabolic, neurological, oncologic conditions. Fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) have emerged as prospective therapeutic procedures to restore microbial and metabolic balance in the gut. This review assesses the latest advancements, challenges, and therapeutic efficacy of FMT and LBPs, highlighting the need for standardization, safety, and long-term evaluation to optimize their clinical application.",

keywords = "CDI, FMT, Gut microbiome, IBD, LBP, cancer, dysbiosis, metabolic disorders, neurological disorders",

author = "Kim, {Do Yeon} and Lee, {So Yeon} and Lee, {Jae Yun} and Whon, {Tae Woong} and Lee, {June Young} and Jeon, {Che Ok} and Bae, {Jin Woo}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2024",

doi = "10.1080/19490976.2024.2412376",

language = "English",

volume = "16",

journal = "Gut Microbes",

issn = "1949-0976",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - Gut microbiome therapy

T2 - fecal microbiota transplantation vs live biotherapeutic products

AU - Kim, Do Yeon

AU - Lee, So Yeon

AU - Lee, Jae Yun

AU - Whon, Tae Woong

AU - Lee, June Young

AU - Jeon, Che Ok

AU - Bae, Jin Woo

PY - 2024

Y1 - 2024

N2 - The human intestine hosts a complex ecosystem of various microorganisms, collectively known as the gut microbiome, which significantly impacts human health. Disruptions in the gut microbiome are linked to various disorders, including gastrointestinal diseases, such as Clostridioides difficile infection and inflammatory bowel disease, as well as metabolic, neurological, oncologic conditions. Fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) have emerged as prospective therapeutic procedures to restore microbial and metabolic balance in the gut. This review assesses the latest advancements, challenges, and therapeutic efficacy of FMT and LBPs, highlighting the need for standardization, safety, and long-term evaluation to optimize their clinical application.

AB - The human intestine hosts a complex ecosystem of various microorganisms, collectively known as the gut microbiome, which significantly impacts human health. Disruptions in the gut microbiome are linked to various disorders, including gastrointestinal diseases, such as Clostridioides difficile infection and inflammatory bowel disease, as well as metabolic, neurological, oncologic conditions. Fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) have emerged as prospective therapeutic procedures to restore microbial and metabolic balance in the gut. This review assesses the latest advancements, challenges, and therapeutic efficacy of FMT and LBPs, highlighting the need for standardization, safety, and long-term evaluation to optimize their clinical application.

KW - CDI

KW - FMT

KW - Gut microbiome

KW - IBD

KW - LBP

KW - cancer

KW - dysbiosis

KW - metabolic disorders

KW - neurological disorders

UR - http://www.scopus.com/inward/record.url?scp=85205791855&partnerID=8YFLogxK

U2 - 10.1080/19490976.2024.2412376

DO - 10.1080/19490976.2024.2412376

M3 - Review article

C2 - 39377231

AN - SCOPUS:85205791855

SN - 1949-0976

VL - 16

JO - Gut Microbes

JF - Gut Microbes

IS - 1

M1 - 2412376

ER -

Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this